Skip to main content

stock

QUIT · ACHIEVE LIFE SCIENCES, INC.

No insider buys or sales filed in 90 days; last 8-K filed Nov 10: results.

Follow QUIT free

Price

Loading the QUIT chart…

Chart by TradingView

The business

What the company does and what it reports, from its SEC filings.

What it is

We are a late-stage clinical specialty pharmaceutical company with the sole mission to address the global nicotine dependence epidemic through the development and commercialization of cytisinicline. There are an estimated 29 million adults in the United States alone who smoke combustible cigarettes and an estimated 17 million adults in the United States who utilize e-cigarettes. Tobacco use is currently the leading cause of preventable death and is responsible for more than eight million deaths worldwide and nearly half a million deaths in the United States annually. More than 87% of lung cancer deaths, 61% of all pulmonary disease deaths, and 32% of all deaths from coronary heart disease are attributable to smoking and exposure to secondhand smoke. Our primary focus is to address this global epidemic.

From the 10-K for the fiscal year ended Dec 31, 2025, filed Mar 24, 2026.

Read the 10-K on SEC
Sector
Life Sciences (SEC office)
Industry
In Vitro & In Vivo Diagnostic Substances (SIC 2835)
Employees
Not stated in the 10-K.
Headquarters
Seattle, WA
Incorporated in
DE
Fiscal year ends
December
Exchange
Nasdaq
Fractional shares
Yes
Listed options
Yes
Filer category
Non-accelerated filer<br>Smaller reporting company
Formerly
ONCOGENEX PHARMACEUTICALS, INC. (until 2017); SONUS PHARMACEUTICALS INC (until 2008)
Shares outstanding
110,034,457 as of Nov 10, 2026 (XBRL frame CY2026Q3I)
Filer (SEC EDGAR)
EDGAR filing index

Key stats

Valuation and the ratios that use the live price are free with an account.

Start free to see this

Deep value

NCAV
$177.72M
NCAV per share
$1.62
NNWC
$34.04M
NNWC per share
$0.31

Expectations

Free cash flow, FY2025
-$49.47M
Free cash growth, last 5 years
—
Revenue growth, last 5 years
—

Margins

Gross
—
Operating
—
Net
—

Returns

ROE
-61.8%
ROA
-54.1%

Health

Current ratio
10.5x
Debt/equity
—

Trailing twelve months to Sep 30, 2026; balance sheet at Sep 30, 2026.

Debt is long-term debt and its current portion. Commercial paper and short-term borrowings are not counted.

Results

Period endRevenueGross profit (not reported by this company)Operating incomeNet incomeFiling
Sep 30, 2026——Gross profit: unreported by this company.—-$12.11M
10-Q filed Nov 10, 2026
Jun 30, 2026——Gross profit: unreported by this company.—-$74.77M
10-Q filed Nov 10, 2026
Mar 31, 2026——Gross profit: unreported by this company.—-$10.17M
10-Q filed Nov 10, 2026
Dec 31, 2025——Gross profit: unreported by this company.—-$14.66M
DEF 14A filed Jun 8, 2026
Derived: the full year minus the first three quarters, not a figure this filer reported as a quarter.
Sep 30, 2025——Gross profit: unreported by this company.—-$14.44M
10-Q filed Nov 10, 2026
Jun 30, 2025——Gross profit: unreported by this company.—-$12.72M
10-Q filed Nov 10, 2026
Mar 31, 2025——Gross profit: unreported by this company.—-$12.83M
10-Q filed Nov 10, 2026
Dec 31, 2024——Gross profit: unreported by this company.—-$12.36M
DEF 14A filed Jun 8, 2026
Derived: the full year minus the first three quarters, not a figure this filer reported as a quarter.
Cash
$59.74M
Debt
—
Net cash
—
Current assets
$203.41M
Current liabilities
$19.39M
Working capital
$184.03M
Total liabilities
$25.69M
Assets
$206.42M
Equity
$180.73M

Balance as of Sep 30, 2026.

SEC data as of Nov 17, 2026

Earnings moves

ReportReaction day
Aug 11, 2026 After the closeAug 12, 2026
May 12, 2026 Before the openMay 12, 2026
Mar 24, 2026 Before the openMar 24, 2026
Nov 6, 2025 Before the openNov 6, 2025

How the price moved after each report: Start free to see this

Next report: Nov 19, 2026

What happened after past reports, not a forecast. Report dates from SEC 8-K results filings (Item 2.02) since Oct 6, 2025; moves from daily closes.

Ten years

Fiscal year endRevenueOperating incomeNet incomeFree cash flow
Dec 31, 2025——-$54.65M-$49.47M
Dec 31, 2024——-$39.83M—
Dec 31, 2023——-$29.82M-$24.50M
Dec 31, 2022——-$42.35M—
Dec 31, 2021——-$33.15M—
Dec 31, 2020——-$14.73M-$13.49M
Dec 31, 2019$0—-$16.39M-$15.27M
Dec 31, 2018$0—-$12.69M-$10.67M
Dec 31, 2017——-$10.58M—
Dec 31, 2016——-$1.23M-$248,000

What it filed

Material events and 5% ownership filings from the last year.

Company filings

since Tue May 12 · 1 offering filing in 12 months · since Fri Aug 14

events

  • Results
    Nov 108-K
  • Executive or director change

    CFO succession

    Oct 18-K
  • Other event
    Aug 148-K
  • Results
    Aug 118-K
  • Bylaws or fiscal year changeShareholder vote results
    Jul 68-K
  • Executive or director change
    Jun 28-K

5% owners ()

Owners and trading

Insider, politician and fund moves, short interest, and the volume traded off the exchange.

Insiders, politicians and funds

Insider trades, last 90 days

No insider buys or sales filed in the last 90 days.

Politician trades, last 90 days

No politician trades filed in the last 90 days.

Funds

None of the tracked funds held this at their last 13F.

Short interest

Easy to borrow

Off-exchange short volume, 20 days

73.0%

Through Nov 16, 2026

Of the volume reported to FINRA's off-exchange facilities, market makers' hedging included. It is not short interest.

Short interest and short volume: FINRA

Off-exchange and dark pools

No off-exchange data

FINRA has no off-exchange data for QUIT yet.

Members see

  • Signals: which strategies fired on QUIT, and the evidence behind each
  • Options positioning: the levels dealers are hedged around
  • Technicals: trend and momentum readings
  • Earnings moves: how the price moved after each report
  • News: stories counted once across outlets
Start free to see these

Comments · 0

No comments yet.

Be the first to say something about QUIT.

nakagai

Signals on QUIT come from a rule, not a model.

Nakagai’s scanner records a signal the moment a strategy’s rule matches on the bars. Members read those signals on their own desk, where an agent journals the tape and briefs them in plain English.

Follow QUIT free

Not financial advice. Read the terms that govern posting here.